{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:21:54Z","timestamp":1790713314524,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":48,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd006790.pub2","type":"reference-entry","created":{"date-parts":[[2008,6,30]],"date-time":"2008-06-30T13:04:46Z","timestamp":1214831086000},"source":"Crossref","is-referenced-by-count":11,"title":["Type I interferons for induction of remission in ulcerative colitis"],"prefix":"10.1002","author":[{"given":"Cynthia H","family":"Seow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric I","family":"Benchimol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Hillary","family":"Steinhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,16]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD006790.pub2-BIB1|cit1","first-page":"1807","article-title":"An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis","volume":"96","author":"Madsen","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1002\/14651858.CD006790.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1542-3565(05)00208-9","article-title":"Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial","volume":"3","author":"Musch","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1002\/14651858.CD006790.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gut.52.9.1286","article-title":"Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study","volume":"52","author":"Nikolaus","year":"2003","journal-title":"Gut"},{"issue":"12","key":"10.1002\/14651858.CD006790.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1136\/gut.52.12.1728","article-title":"A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis","volume":"52","author":"Tilg","year":"2003","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD006790.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2005.02556.x","article-title":"Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study","volume":"22","author":"Bargiggia","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD006790.pub2-BIB6|cit6","first-page":"1323","article-title":"Interferon alpha-2A (roferon) as a treatment of inflammatory bowel disease in children and adolescents","volume":"371B","author":"Hadziselimovic","year":"1995","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1002\/14651858.CD006790.pub2-BIB7|cit7","first-page":"31","article-title":"[Interferon status of patients with non-specific ulcerous colitis and its correction with interferon inducers]","volume":"74","author":"Maev","year":"2002","journal-title":"Terapevticheskii Arkhiv"},{"issue":"7","key":"10.1002\/14651858.CD006790.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1046\/j.1365-2036.2002.01264.x","article-title":"Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis - an open long-term pilot trial","volume":"16","author":"Musch","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1002\/14651858.CD006790.pub2-BIB9|cit9","first-page":"597","article-title":"Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis","volume":"7","author":"Sumer","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1002\/14651858.CD006790.pub2-BIB10|cit10","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID) Interferon-beta treatment of ulcerative colitis Clinicaltrials.gov"},{"key":"10.1002\/14651858.CD006790.pub2-BIB11|cit11","unstructured":"Merck Serono International S.A A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II study of subcutaneously administered IFN-beta-1a in the treatment of patients with moderately active ulcerative colitis (UC) Direct communication with Serono"},{"issue":"9139","key":"10.1002\/14651858.CD006790.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","volume":"352","author":"Anonymous","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD006790.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1212\/WNL.56.12.1628","article-title":"PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS","volume":"56","author":"Anonymous","year":"2001","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD006790.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/10799900260475696","article-title":"A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis","volume":"22","author":"Antonetti","year":"2002","journal-title":"J Interferon Cytokine Res"},{"issue":"9573","key":"10.1002\/14651858.CD006790.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006790.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00005176-199605000-00006","article-title":"Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis","volume":"22","author":"Beattie","year":"1996","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/BOR.0b013e328010c547","article-title":"Syndromes and complications of interferon therapy","volume":"19","author":"Borg","year":"2007","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"10.1002\/14651858.CD006790.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nri1132","article-title":"The immunological and genetic basis of inflammatory bowel disease","volume":"3","author":"Bouma","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1002\/14651858.CD006790.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1189\/jlb.71.4.565","article-title":"Interferon-alpha as an immunotherapeutic protein","volume":"71","author":"Brassard","year":"2002","journal-title":"J Leukoc Biol"},{"issue":"7109","key":"10.1002\/14651858.CD006790.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD006790.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"10.1002\/14651858.CD006790.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2036.2004.02170.x","article-title":"Review article: pegylated interferons: chemical and clinical differences","volume":"20","author":"Foster","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1002\/14651858.CD006790.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/gut.2005.090134","article-title":"Interfering with interferons in inflammatory bowel disease","volume":"55","author":"Ghosh","year":"2006","journal-title":"Gut"},{"issue":"1-2","key":"10.1002\/14651858.CD006790.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jneuroim.2007.01.011","article-title":"Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response","volume":"185","author":"Graber","year":"2007","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1002\/14651858.CD006790.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/0016-5085(89)90905-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD006790.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.MIB.0000195385.19268.68","article-title":"Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities","volume":"12 Suppl 1","author":"Hanauer","year":"2006","journal-title":"Inflamm Bowel Dis"},{"issue":"7414","key":"10.1002\/14651858.CD006790.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"23","key":"10.1002\/14651858.CD006790.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMct061675","article-title":"Peginterferon and ribavirin for chronic hepatitis C","volume":"355","author":"Hoofnagle","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"8706","key":"10.1002\/14651858.CD006790.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0140-6736(90)91521-B","article-title":"Preliminary report: cyclosporin in treatment of severe active ulcerative colitis","volume":"336","author":"Lichtiger","year":"1990","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD006790.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0168-8278(01)00022-8","article-title":"Ulcerative colitis associated with interferon treatment for chronic hepatitis C","volume":"34","author":"Mavrogiannis","year":"2001","journal-title":"J Hepatol"},{"issue":"3","key":"10.1002\/14651858.CD006790.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","article-title":"Side effects of high-dose interferon therapy for chronic hepatitis C","volume":"25","author":"Okanoue","year":"1996","journal-title":"J Hepatol"},{"issue":"7","key":"10.1002\/14651858.CD006790.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3109\/00365527809182199","article-title":"A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis","volume":"13","author":"Powell-Tuck","year":"1978","journal-title":"Scand J Gastroenterol"},{"issue":"6666","key":"10.1002\/14651858.CD006790.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","article-title":"Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial","volume":"298","author":"Rachmilewitz","year":"1989","journal-title":"BMJ"},{"issue":"26","key":"10.1002\/14651858.CD006790.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1002\/14651858.CD006790.pub2-BIB36|cit36","first-page":"971","article-title":"An index of disease activity in patients with ulcerative colitis","volume":"87","author":"Seo","year":"1992","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaci.2005.03.016","article-title":"Differential effects of IFN-alpha on the expression of various TH2 cytokines in human CD4+ T cells","volume":"116","author":"Shibuya","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1002\/14651858.CD006790.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/1097-0142(19911001)68:7<1538::AID-CNCR2820680714>3.0.CO;2-2","article-title":"Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha","volume":"68","author":"Sparano","year":"1991","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD006790.pub2-BIB39|cit39","first-page":"438","article-title":"Acute ulcerative colitis during successful interferon\/ribavirin treatment for chronic hepatitis","volume":"54","author":"Sprenger","year":"2005","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD006790.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/BF02355061","article-title":"Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C","volume":"31","author":"Tada","year":"1996","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub2-BIB41|cit41","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000478.pub2","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","author":"Timmer","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006790.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2036.2006.03070.x","article-title":"Review article: induction therapy for patients with active ulcerative colitis","volume":"24 Suppl 1","author":"Travis","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"4947","key":"10.1002\/14651858.CD006790.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"issue":"11","key":"10.1002\/14651858.CD006790.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1111\/j.1572-0241.2002.07029.x","article-title":"Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis","volume":"97","author":"Tsukada","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1002\/14651858.CD006790.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ibd.20152","article-title":"Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C","volume":"13","author":"Tursi","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"1-2","key":"10.1002\/14651858.CD006790.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000090316","article-title":"Emerging biological treatments in inflammatory bowel diseases","volume":"24","author":"Assche","year":"2006","journal-title":"Digestive Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006790.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"issue":"11","key":"10.1002\/14651858.CD006790.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2006.105197","article-title":"A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin","volume":"55","author":"Watanabe","year":"2006","journal-title":"Gut"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006790.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T00:00:00Z","timestamp":1442188800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006790.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T01:10:20Z","timestamp":1684458620000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006790.pub2"}},"subtitle":[],"editor":[{"given":"Cynthia H","family":"Seow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,7,16]]},"references-count":48,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006790.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD006790.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2008,7,16]]}}}